Seventure Partners: A Major Pharmaceutical Company Participates as Strategic Investor in Health for Life Capital™ the First Investment Vehicle Focused on the Microbiome Health and Nutrition Revolutionary Sector
Seventure Partners, a European leader in financing innovation, today announced the completion of a new closing for Health for Life Capital ™, the first investment vehicle in the world to anticipate the microbiome revolution in the fields of health and nutrition, with Novartis Pharma AG agreeing to participate. This closing will increase the total amount of funds available to €160Mio.
Since the launch of Health for Life Capital™ in December of 2013, Seventure Partners has proven its strategic vision by anticipating the microbiome revolution in the health and nutrition sectors. Around this vision, Seventure Partners has successfully attracted financial investors, strategic industrialists and entrepreneurs. As a result, Health for Life Capital™ has become a reference in its field.
Health for Life Capital ™ has invested in a unique and specific portfolio of pioneering companies in the field of the microbiome and nutrition, such as the highly promising Enterome, LNC, Maat pharma, Eligo bioscience, Targedys, Micropharma and others
“Seventure Partners believes that large worldwide pharmaceutical groups are increasingly interested in the microbiome field in anticipation of finding new ways to conduct research and developing drugs with accompanying diagnostics; especially for infectious and gastrointestinal diseases, and other indications, as well as immuno-oncology approaches” said Isabelle de Cremoux, CEO and Managing Partner of Seventure.
Continuing, "The very rapid progression of microbiome research gives some answers to the growing problem of chronic inflammatory diseases, addressing their treatment and prevention and sustainably influencing the pharmaceutical, food and diagnostic industries. It will also impact the entire chain of stakeholders in the health field (public authorities, insurance, etc.). This explains why we wanted to unite specific strategic players from all areas as investors in Health for Life Capital™. The microbiome revolution will have an impact in the veterinary and agricultural fields as well as in human healthcare. Current and future research advancements will have a human, social and economic impact worldwide Since the biotechnology sector started in the 1980s, we are now witnessing the emergence of a new sector that will be as important as genomics.”
Health for Life Capital™ relies on a wide network of industrial partners (Danone, Tereos, Lesaffre, Bel, Tornier and now Novartis Pharma) and experts such as INRA (Institut National de Recherche Agronomique), the Danish Technology Institute (DTI), and Chalmers University of Technology in Gothenburg.
The MultiCap Growth funds, managed by Bpifrance Investment under the PIA (program of investments for the future), has also invested in Health for Life Capital TM .
Legal note: The Health for Life Capital investment vehicle is composed of a Luxembourg SICAR and a French FPCI (AIF fund). Seventure Partners acts as an Investment Advisor of the SICAR (Health for Life Management) General Partner, and as the Management Company of the FPCI. This Information is only intended for professional investors. Health for Life Capital™ bears a high risk. Investors could lose all of their investment.
Notes to Editors
About the Human Microbiome: The Human intestinal microbiota is a complex personal ecosystem, usually stable, tightly adapted to the human host and in constant symbiotic interaction with his cells and organs. There are nevertheless numerous conditions and clinical practices that impose stress to the balanced microbiota. The word microbiota represents an ensemble of microorganisms that resides in a previously established environment. The gut microbiota (formerly called gut flora) is the name given today to the microbe population living in human beings intestine. It contains tens of trillions of microorganisms, including at least 1000 different species of known bacteria with more than 3 million genes (150 times more than human genes). Microbiota can, in total, weigh up to 2 kg. One third of the human gut microbiota is common to most people, while two thirds are specific to each person. The microbiota fulfils physiological functions that have a direct impact on health:
• It helps the body to digest certain foods that the stomach and small intestine have not been able to digest.
• It helps with the production of some vitamins (B and K).
• It helps to combat aggressions from other microorganisms, maintaining the wholeness of the intestinal mucosa.
• It plays an important role in the immune system, performing a barrier effect.
• A healthy and balanced gut microbiota is key to ensuring proper digestive functioning.
About Seventure Partners
Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure has invested in innovative businesses with high growth potential in digital technologies in France and Germany and in the life sciences field across Europe and North America, with currently over €500m in assets under management as of the end of 2014.
In life sciences, the four areas of focus include biotechnology and pharmaceuticals, connected health and medtech, industrial biotechnology and cleantech, and last but not least: the microbiome, nutrition, personalized medicine and food. Seventure Partners also considers investments in the field of diagnostics, biomarkers, drug delivery systems, lifestyle healthcare and services.
Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage. In December 2013, Seventure Partners successfully launched its Health for Life Capital™ which has attracted strategic investments from prestigious organizations including Danone, Tereos, Tornier, Lesaffre, Bel and Novartis as well as entrepreneurs and financial institutions.
Seventure is a subsidiary of Natixis Global Asset Management. Natixis is the corporate investment management and financial services arm of Groupe BPCE, the second-largest French bank.
For more details: www.seventure.fr
At the Company
Isabelle de Cremoux
Président du directoire, CEO and managing partner
Tél : + 33 1 58 19 22 72
Email : email@example.com
Tél : +33 1 53 63 27 35
Email : firstname.lastname@example.org
Sue Charles/ Gemma Howe
Tel: +44 20 7866 7860
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Edgewater Networks Announces Event Sponsorship of BroadSoft Connections 201720.10.2017 21:00 | Pressemelding
Edgewater Networks, Inc., the industry leader in Network Edge Orchestration, announced today that it is an event sponsor of the BroadSoft Connections 2017 user conference, which takes place October 22-25 at the JW Marriott Phoenix Desert Ridge Resort & Spa in Phoenix, AZ. During the event, Edgewater Networks will feature demonstrations of the latest end-to-end network interoperability capabilities, including Zero Touch Provisioning, UC Analytics from the core to the endpoint, SD-WAN optimized for BroadSoft, and much more. Continuing a long-standing partnership with BroadSoft, Edgewater Networks has completed another level of BroadCloud certification, this time for local survivability which is critical for business continuity for SMB and Enterprise customers. BroadSoft’s PacketSmart is available on all EdgeMarc Intelligent Edges. All elements of the Network Edge Orchestration are
More than 70 Companies to Showcase Top Tech at CES Unveiled Paris20.10.2017 15:08 | Pressemelding
The Consumer Technology Association (CTA) today announced that more than 70 exhibitors will showcase their latest innovations at the now sold-out fifth annual CES Unveiled Paris The event will focus on the Internet of Things (IoT), connectivity and smart cities, and draw more than 600 attendees. CES Unveiled Paris will run from 2-7:30 PM on Tuesday, October 24, 2017 at the Palais Brongniart. Regional technology companies, top-tier media outlets, buyers and key industry influencers will come together at CES Unveiled Paris to get a direct look at the latest industry developments. The day kicks off with a CES news conference and CTA market trends presentation. Conference programming is followed by a tabletop exhibition & networking reception. Curated exhibitors will be there to showcase top tech from robotics and audio to smart home and augmented and virtual reality. Notable
Westinghouse Receives Regulatory Approval for Analysis Methodologies20.10.2017 12:15 | Pressemelding
Westinghouse Electric Company today announced that it has received approval from the U.S. Nuclear Regulatory Commission (NRC) for two new important analysis methodologies that will be used to upgrade Westinghouse- and Combustion Engineering-based nuclear steam supply system (NSSS) safety analyses. The approvals granted are for the new FULL SPECTRUMTM Loss of Coolant Accident (FSLOCATM) methodology and the Performance Analysis and Design Model software code update, PAD5. FSLOCA is capable of improved modeling of the transient response in a pressurized water reactor to the full spectrum of LOCA break sizes that could occur, and PAD5 is the next generation of the Westinghouse fuel rod design performance code. “These codes were developed to work in concert with each other to maximize analytical margin for nuclear utilities,” said Michele DeWitt, senior vice preside
Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®20.10.2017 12:03 | Pressemelding
Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from studies of Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in HCV-infected patients with severe renal impairment, Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in HCV-infected liver transplant recipients and Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) in NS5A-inhibitor experienced HCV-infected patients will be presented during poster sessions on October 21 and October 22. In addition, updated results f
Schlumberger Announces Third-Quarter 2017 Results20.10.2017 11:00 | Pressemelding
Schlumberger Limited (NYSE:SLB) today reported results for the third quarter of 2017. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2017 Jun. 30, 2017 Sept. 30, 2016 Sequential Year-on-year
SP3H Announces That It Has Obtained a €1.2 Million European Union Grant for Its Intelligent and Clean Vehicle (VIP) Project20.10.2017 10:47 | Pressemelding
SP3H is proud to announce joining the very select circle of the 10 French winners of the H2020 SME Instrument Phase 2 program since 2014. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005325/en/ Last summer VIP received the very prestigious SME instrument phase 2 H2020 label in the "transport & smart cities mobility" category. With an overall budget of € 1.7 million, VIP is subsidized by the European Union at a rate of 70% or €1.2 million. The framework contract was officially signed early October. VIP is the pre-industrialization program for Fuelbox sensors, the world's first miniaturized scanner capable of analyzing the quality of fuels on board vehicles. The heart of the program remains closely linked to the reduction of CO2 and pollutant emissions from vehicle
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom